Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Ligand pharmaceuticals incorporated symbols : Snynf save search
Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
Published: 2022-12-05 (Crawled : 13:00) - biospace.com/
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: -1.11%
H: 0.16%
C: -1.38%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -0.43%
H: 1.0%
C: -3.66%
pharmaceuticals ceo
Ligand Announces Completion of OmniAb Spin-Off
Published: 2022-11-01 (Crawled : 22:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 7.74%
H: 0.17%
C: 0.17%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: 0.0%
H: 1.5%
C: -3.47%
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-10-26 (Crawled : 12:20) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
AHPA 4 | $6.125 -9.26% 4.33%
|
|
| O: -5.1%
H: 1.72%
C: -8.48%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.12%
H: 0.0%
C: 0.0%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: 0.48%
H: 2.13%
C: -0.81%
treatment fda approval
Avista Public Acquisition Corp. II Announces Effectiveness of Registration Statement and Sets Date for Extraordinary General Meeting to Vote on Proposed Business Combination
Published: 2022-10-03 (Crawled : 12:20) - prnewswire.com
AHPA 4 | $6.125 -9.26% 4.33%
|
|
| O: 0.39%
H: 0.1%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: 0.12%
H: 2.95%
C: 0.95%
acquisition meeting
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-08-24 (Crawled : 22:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -4.66%
H: 0.0%
C: -1.69%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -0.75%
H: 3.45%
C: 2.49%
tecvayli treatment approval
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Aug 02, 2022
Published: 2022-08-02 (Crawled : 06:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 3.91%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.11%
H: 0.0%
C: 0.0%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -0.97%
H: 5.07%
C: 3.85%
nasdaq grants
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
Published: 2022-06-29 (Crawled : 22:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -0.63%
H: 2.13%
C: 2.1%
Ligand to Report First Quarter Financial Results on May 4
Published: 2022-04-19 (Crawled : 22:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: 0.87%
H: 1.96%
C: 1.58%
report results
Ligand to Report Fourth Quarter Financial Results on February 17
Published: 2022-02-09 (Crawled : 20:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 2.73%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.43%
H: 0.0%
C: 0.0%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: 1.07%
H: 1.67%
C: 0.37%
financial results report results
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
Published: 2021-12-22 (Crawled : 13:30) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.59%
H: 1.12%
C: 0.93%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: 0.73%
H: 3.33%
C: 2.86%
cejemly treatment ema als approval cel lung cancer china therapy cancer
Ligand and GSK Expand Global Collaboration and License Agreement
Published: 2021-12-21 (Crawled : 22:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.76%
H: 0.67%
C: 0.45%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -0.12%
H: 0.06%
C: -1.31%
license collaboration
Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
Published: 2021-10-21 (Crawled : 14:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.08%
H: 0.41%
C: 0.41%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -0.17%
H: 1.8%
C: 0.91%
covid collaboration technology
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.